0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. "This is a very significant positive in our view and has both long-term and short-term upside ramifications." Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 03:38 ET (08:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.